Skip to main content
Clinical Trials/NCT02063321
NCT02063321
Unknown
Not Applicable

Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic

Emil Martinka0 sites762 target enrollmentDecember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetic Macular Edema
Sponsor
Emil Martinka
Enrollment
762
Primary Endpoint
Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema
Last Updated
12 years ago

Overview

Brief Summary

The aim of the study is to find out prevalence of diabetic macular edema (DME) in patients with diabetes mellitus in Slovak Republic.The outcome of the project will be epidemiology survey, prevalence of wet form of Diabetic Macular Edema in relation to duration of diabetes, type of diabetes, treatment (insulin vs. OAD or combination) etc. and identification of prognostic factors leading to development of DME.

Detailed Description

Epidemiological study, prospective, non-interventional 1. Patient with history of diabetes ≥ 10 years or with suspected visual impairment will be enrolled and screened in NIED during hospitalization 2. Anamnesis and history of diabetes, other co-morbidities, treatment will be recorded 3. Patient undergo in NIED detailed diabetology examination and basic ophthalmology examination (best non-corrected visual acuity in ETDRS score and Amsler grid test) 4. Patient undergo in NIED examination of the back of the eye using fundus camera to take images of retina to assess long-term changes of macula, optic disc, retina vessels and surrounding tissues 5. The assessment of the ophthalmology examination will be carried out in one of two specialized reading centers - II. Eye Clinic SZU FNsP F.D.R., Banská Bystrica or OFTAL Specialized Hospital for Ophthalmology, Zvolen by Retina specialist The process of screening will be continuous, whilst each patient will sign an informed consent. Patients records will be stored electronically and data transmission between NIED and Reading Center will be protected using validated and secured software.

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
December 2015
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Emil Martinka
Responsible Party
Sponsor Investigator
Principal Investigator

Emil Martinka

Head of Diabetology Department

National Institute of Endocrinology and Diabetology, Slovakia

Eligibility Criteria

Inclusion Criteria

  • Adults ≥18 years treated in National Institute of Endocrinology and Diabetology
  • Patients diagnosed with Diabetes mellitus type I and type 2 respectively
  • Presence of Diabetes ≥10 years or patients with suspected visual impairment (duration of diabetes \<10 years)
  • Signed patient´s information and informed content

Exclusion Criteria

  • Non-compliant patients

Outcomes

Primary Outcomes

Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema

Time Frame: Patients screened during hospitalization in National Institute of Endocrinology and Diabetology (NIED), usually in 10 days

Image of fundus taken in NIED securely sent via internet and electronic Clinical Report Form (eCRF) to ophthalmology reading center to assess stage and severity of potential retina damage, feedback to NIED within the stay of screened individual essential for further disease management

Secondary Outcomes

  • Patient´s structure with DME and clinically significant DME in terms of demography and anamnesis of diabetes(Patients screened during hospitalization in NIED, usually in 10 days)
  • Range of visual deterioration and occurence of blindness in relation to duration of diabetes(Patients screened during hospitalization in NIED, usually in 10 days)
  • Prognostic factors, which determine the occurence of DME using explorative analysis(Patients screened during hospitalization in NIED, usually in 10 days)
  • Range of visual deterioration and occurence of blindness in relation to type of diabetes(Patients screened during hospitalization in NIED, usually in 10 days)
  • Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy)(Patients screened during hospitalization in NIED, usually in 10 days)

Similar Trials